Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Ablinger M, Felder TK, Wimmer M, Zauner R, Hofbauer P, Lettner T, Wolkersdorfer M, Lagler FB, Diem A, Bauer JW, Wally V.

Orphanet J Rare Dis. 2018 Nov 1;13(1):193. doi: 10.1186/s13023-018-0940-1.

2.

A survey of medicine use in children and adolescents in Austria.

Rauch E, Lagler FB, Herkner H, Gall W, Sauermann R, Hetz S, Male C.

Eur J Pediatr. 2018 Oct;177(10):1479-1487. doi: 10.1007/s00431-018-3196-9. Epub 2018 Jul 5.

PMID:
29978258
3.

Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial.

Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, Ablinger M, Felder TK, Hofbauer P, Wolkersdorfer M, Lagler FB, Hitzl W, Laimer M, Kitzmüller S, Diem A, Bauer JW.

J Am Acad Dermatol. 2018 May;78(5):892-901.e7. doi: 10.1016/j.jaad.2018.01.019. Epub 2018 Feb 2.

4.

Pompe disease in Austria: clinical, genetic and epidemiological aspects.

Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, Moser H, Möslinger D, Freilinger M, Lagler F, Grinzinger S, Reichhardt M, Bittner RE, Schmidt WM, Lex U, Brunner-Krainz M, Quasthoff S, Wanschitz JV.

J Neurol. 2018 Jan;265(1):159-164. doi: 10.1007/s00415-017-8686-6. Epub 2017 Nov 27.

5.

Question 1: How safe are ACE inhibitors for heart failure in children?

van der Meulen M, Dalinghaus M, Burch M, Szatmari A, Castro Diez C, Khalil F, Swoboda V, Breur J, Bajcetic M, Jovanovic I, Lagler FB, Klingmann I, Laeer S, de Wildt SN.

Arch Dis Child. 2018 Jan;103(1):106-109. doi: 10.1136/archdischild-2017-312774. Epub 2017 Oct 26. No abstract available.

PMID:
29074732
6.

[Lysosomal Storage Diseases: Challenges in Multiprofessional Patient Care with Enzyme Replacement Therapy].

Das AM, Lagler F, Beck M, Scarpa M, Lampe C.

Klin Padiatr. 2017 May;229(3):168-174. doi: 10.1055/s-0043-103088. Epub 2017 May 2. German.

PMID:
28464188
7.

Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug.

Marschallinger J, Schäffner I, Klein B, Gelfert R, Rivera FJ, Illes S, Grassner L, Janssen M, Rotheneichner P, Schmuckermair C, Coras R, Boccazzi M, Chishty M, Lagler FB, Renic M, Bauer HC, Singewald N, Blümcke I, Bogdahn U, Couillard-Despres S, Lie DC, Abbracchio MP, Aigner L.

Nat Commun. 2015 Oct 27;6:8466. doi: 10.1038/ncomms9466.

8.

Enduring and emerging challenges of informed consent.

Lagler FB, Weineck SB, Schwab M.

N Engl J Med. 2015 May 28;372(22):2170-1. doi: 10.1056/NEJMc1503813. No abstract available.

PMID:
26017841
9.

The Kuvan(®) Adult Maternal Paediatric European Registry (KAMPER) Multinational Observational Study: Baseline and 1-Year Data in Phenylketonuria Patients Responsive to Sapropterin.

Trefz FK, Muntau AC, Lagler FB, Moreau F, Alm J, Burlina A, Rutsch F, Bélanger-Quintana A, Feillet F; KAMPER investigators.

JIMD Rep. 2015;23:35-43. doi: 10.1007/8904_2015_425. Epub 2015 Mar 31.

10.

Pharmacokinetics of intravenous amiodarone in children.

Ramusovic S, Läer S, Meibohm B, Lagler FB, Paul T.

Arch Dis Child. 2013 Dec;98(12):989-93. doi: 10.1136/archdischild-2013-304483. Epub 2013 Sep 19.

PMID:
24051016
11.

Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study.

Wally V, Kitzmueller S, Lagler F, Moder A, Hitzl W, Wolkersdorfer M, Hofbauer P, Felder TK, Dornauer M, Diem A, Eiler N, Bauer JW.

Orphanet J Rare Dis. 2013 May 7;8:69. doi: 10.1186/1750-1172-8-69.

12.

The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).

Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ; HOS Natural History Working Group on behalf of HOS Investigators.

Mol Genet Metab. 2013 May;109(1):41-8. doi: 10.1016/j.ymgme.2013.03.001. Epub 2013 Mar 14.

13.

Evaluation of a portable nephelometer against the Tapered Element Oscillating Microbalance method for monitoring PM(2.5).

Karagulian F, Belis CA, Lagler F, Barbiere M, Gerboles M.

J Environ Monit. 2012 Aug;14(8):2145-53. doi: 10.1039/c2em30099k. Epub 2012 Jul 6.

PMID:
22766850
14.

Prevalence of tetrahydrobiopterine (BH4)-responsive alleles among Austrian patients with PAH deficiency: comprehensive results from molecular analysis in 147 patients.

Sterl E, Paul K, Paschke E, Zschocke J, Brunner-Krainz M, Windisch E, Konstantopoulou V, Möslinger D, Karall D, Scholl-Bürgi S, Sperl W, Lagler F, Plecko B.

J Inherit Metab Dis. 2013 Jan;36(1):7-13. doi: 10.1007/s10545-012-9485-y. Epub 2012 Apr 25.

PMID:
22526846
15.

Novel pharmacological chaperones that correct phenylketonuria in mice.

Santos-Sierra S, Kirchmair J, Perna AM, Reiss D, Kemter K, Röschinger W, Glossmann H, Gersting SW, Muntau AC, Wolber G, Lagler FB.

Hum Mol Genet. 2012 Apr 15;21(8):1877-87. doi: 10.1093/hmg/dds001. Epub 2012 Jan 13.

PMID:
22246293
16.

New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Lagler FB, Gersting SW, Zsifkovits C, Steinbacher A, Eichinger A, Danecka MK, Staudigl M, Fingerhut R, Glossmann H, Muntau AC.

Biochem Pharmacol. 2010 Nov 15;80(10):1563-71. doi: 10.1016/j.bcp.2010.07.042. Epub 2010 Aug 10.

PMID:
20705059
17.

Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo.

Gersting SW, Lagler FB, Eichinger A, Kemter KF, Danecka MK, Messing DD, Staudigl M, Domdey KA, Zsifkovits C, Fingerhut R, Glossmann H, Roscher AA, Muntau AC.

Hum Mol Genet. 2010 May 15;19(10):2039-49. doi: 10.1093/hmg/ddq085. Epub 2010 Feb 23.

18.

Quantifying the impact of residential heating on the urban air quality in a typical European coal combustion region.

Junninen H, Mønster J, Rey M, Cancelinha J, Douglas K, Duane M, Forcina V, Müller A, Lagler F, Marelli L, Borowiak A, Niedzialek J, Paradiz B, Mira-Salama D, Jimenez J, Hansen U, Astorga C, Stanczyk K, Viana M, Querol X, Duvall RM, Norris GA, Tsakovski S, Wåhlin P, Horák J, Larsen BR.

Environ Sci Technol. 2009 Oct 15;43(20):7964-70. doi: 10.1021/es8032082.

PMID:
19921921
19.

Changes in plasma amino acid concentrations with increasing age in patients with propionic acidemia.

Scholl-Bürgi S, Sass JO, Heinz-Erian P, Amann E, Haberlandt E, Albrecht U, Ertl C, Sigl SB, Lagler F, Rostasy K, Karall D.

Amino Acids. 2010 May;38(5):1473-81. doi: 10.1007/s00726-009-0356-2. Epub 2009 Oct 1.

PMID:
19795187
20.

Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.

Gersting SW, Kemter KF, Staudigl M, Messing DD, Danecka MK, Lagler FB, Sommerhoff CP, Roscher AA, Muntau AC.

Am J Hum Genet. 2008 Jul;83(1):5-17. doi: 10.1016/j.ajhg.2008.05.013. Epub 2008 Jun 5.

Supplemental Content

Loading ...
Support Center